StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities researchers at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

Shares of NERV stock opened at $2.93 on Friday. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The stock has a 50 day moving average price of $2.91 and a two-hundred day moving average price of $2.80. The company has a market capitalization of $20.45 million, a P/E ratio of -0.65 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, equities analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.